PARP1/2/TNKS1/2-IN-1
Based on 1 Customer Validation
PARP1/2/TNKS1/2-IN-1 is a potent and selective dual PARP-1/2 and TNKS1/2 inhibitor with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM for PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 suppresses Wnt/β-catenin signaling, decreases pADPr and BRCA1 expression, induces DNA damage, promotes apoptosis, and arrests the cell cycle at the G2/M phase. PARP1/2/TNKS1/2-IN-1 can be used for the study of on colorectal cancer and triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity : 98.66%
- CAS No.: 2243453-32-7
- Formula: C35H31FN6O5
- Molecular Weight:634.66
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
PARP-1 0.25 nM (IC50) |
PARP-2 1.2 nM (IC50) |
TNKS2 4.15 nM (IC50) |
TNKS1 13.5 nM (IC50) |
PARP-7 15 nM (IC50) |
PARP-10 140 nM (IC50) |
PARP-12 371 nM (IC50) |
PARP-14 1369 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AML12 | CC50 |
117.47 μM
Compound: I-9
|
Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay
Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay
|
[PMID: 35504210] |
| HCT-116 | IC50 |
0.75 μM
Compound: I-9
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
|
[PMID: 35504210] |
| MDA-MB-231 | IC50 |
0.87 μM
Compound: I-9
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
|
[PMID: 35504210] |
| MDA-MB-468 | IC50 |
0.09 μM
Compound: I-9
|
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
|
[PMID: 35504210] |
In Vitro
PARP1/2/TNKS1/2-IN-1 (compound I-9) inhibits PARP-1, PARP-2, TNKS1 and TNKS2 with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM, respectively; it also inhibits PARP-7, PARP-10, PARP-12 and PARP-14 with IC50 values of 15.0 nM, 140.0 nM, 371.0 nM and 1369.0 nM, respectively, and shows weak or no inhibitory activity against 208 tested kinases at 1 μM[1].
PARP1/2/TNKS1/2-IN-1 (0.01-10 μM; 7 days) inhibits MDA-MB-231, HCT116 and MDA-MB-468 cancer cell proliferation, with IC50 values of 0.87 μM, 0.75 μM and 0.09 μM, respectively[1].
PARP1/2/TNKS1/2-IN-1 shows low cytotoxicity in AML12 cells, with a CC50 of 117.47 μM[1].
PARP1/2/TNKS1/2-IN-1 (10 μM) modulates PARP- and Wnt/β-catenin-related signaling in HCT116 cells by decreasing pADPr, active β-catenin, total β-catenin, cyclin D1 and BRCA1 expression, and increasing axin2 expression[1].
PARP1/2/TNKS1/2-IN-1 (1 μM; 72 h) reduces RAD51 foci formation and increases γH2AX nuclear foci in HCT116 cells[1].
PARP1/2/TNKS1/2-IN-1 (1, 5 μM; 3 days) promotes apoptosis and arrests the cell cycle at the G2/M phase in HCT116 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231, HCT116, MDA-MB-468
-
Concentration:0.01-10 μM
-
Incubation Time:7 days
-
Result:Inhibited MDA-MB-231, HCT116, MDA-MB-468 cell proliferation, with IC50 values of 0.87 μM, 0.75 μM and 0.09 μM, respectively.
-
Cell Line:HCT116
-
Concentration:1 μM
-
Incubation Time:72 h
-
Result:Reduced RAD51 foci formation and impaired homologous recombination repair efficiency.
Increased nuclear γH2AX foci, indicating enhanced DNA double-strand damage.
-
Cell Line:HCT116
-
Concentration:1, 5 μM
-
Incubation Time:3 days
-
Result:Promoted HCT116 cell apoptosis. At 5 μM, induced more apoptotic cells than 5 μM Olaparib (HY-10162) and 5 μM E7449 (HY-12418).
-
Cell Line:HCT116
-
Concentration:1, 5 μM
-
Incubation Time:3 days
-
Result:Promoted the G1/S transition and arrested the cell cycle at the G2/M phase at 1 μM and 5 μM.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | C0 | AUC0-t | AUC0-∞ | Vz | CL | MRT0-t | MRT0-∞ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 1 mg/kg | i.v. | 1.73 h | 0.083 h | 28.7 ng/mL | 389.0 ng/mL | 175.6 ng·h/mL | 184.1 ng·h/mL | 13571 mL/kg | 5440 mL/h/kg | 0.77 h | 1.13 h |
In Vivo
PARP1/2/TNKS1/2-IN-1 (500 mg/kg; i.p.; single dose) shows no obvious acute toxicity or intestinal toxicity in Sprague-Dawley rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice, 5-6 weeks old, 18-20 g, subcutaneously inoculated with 5 × 106 HCT116 cells on the right flank[1]
-
Dosage:25, 50, 100 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once daily; for 28 days
-
Result:Suppressed HCT116 xenograft tumor growth in a dose-dependent manner.
Achieved a TGI of 31.73% at 25 mg/k.
Achieved significant antitumor activity at 100 mg/kg, with a TGI of 51.74%.
Reduced tumor volume and tumor weight compared with the control group.
Did not cause remarkable toxicity, side effects or obvious body weight decrease during the 28-day dosing period.
-
Animal Model:Sprague-Dawley rat acute toxicity and intestinal toxicity model, half male and half female[1]
-
Dosage:500 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Caused no rat death after a single-dose administration.
Did not induce significant body weight loss from day 0 to day 7.
Showed no obvious intestinal toxicity in the duodenum, jejunum, ileum and colon according to histopathological analysis.
Chemical Information
-
CAS No. 2243453-32-7
-
Appearance Solid
-
Molecular Weight 634.66
-
Formula C35H31FN6O5
-
Color White to light yellow
-
SMILES
O=C(N1CCN(C(C2=CC(CC3=NNC(C4=C3C=CC=C4)=O)=CC=C2F)=O)CC1)NC5=CC=C(C(NC6=CC=C(OC)C=C6)=O)C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PARP1/2/TNKS1/2-IN-1
- 2243453-32-7
- PARP
- Apoptosis
- Wnt
- β-catenin
- PARP-1 inhibitor
- PARP-2 inhibitor
- TNKS1 inhibitor
- TNKS2 inhibitor
- dual inhibitor
- selective
- Wnt/β-catenin signaling pathway
- pADPr
- axin2
- cyclin D1
- BRCA1
- RAD51
- γH2AX
- apoptosis
- cell cycle arrest
- DNA damage
- MDA-MB-231
- HCT116
- MDA-MB-468
- AML12
- HCT116 xenograft model
- colorectal cancer
- triple-negative breast cancer
- Inhibitor
- inhibitor
- inhibit